Home › Triple-Negative Breast Cancer › Oregon
Triple-Negative Breast Cancer clinical trials in Oregon
12 studies for Triple-Negative Breast Cancer are looking for participants at sites in Oregon.
Cities in Oregon
Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Portland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05867251Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Providence Portland Medical Center ( Site 0116), Portland
- Providence Oncology and Hematology Care Clinic - Westside ( Site 0126), Portland
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06393374A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Northwest Cancer Specialists (Compass Oncology) ( Site 8010), Tigard
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06966700A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Local Institution - 0052, Portland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06618287Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
- Providence Portland Cancer Institute - Franz Clinic, Portland
- Providence St. Vincent Medical Center, Portland
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT06353997The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Oregon Health & Science University (OHSU), Portland
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 15, 2026 · NCT04585750Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- St. Charles Health System, Inc. DBA St. Charles Medical Center, Bend
- Samaritan Hospital, Corvallis
- Willamette Valley Cancer Institute and Research Center, Eugene
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT05633654A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Providence Cancer Center Oncology and Hematology Care- Eastside, Portland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT04895709A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Willamette Valley Cancer Institute, Eugene
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT06926868Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Oncology Associates of Oregon, P.C., Eugene
- Compass Oncology - Rose Quarter, Portland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT05579366I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Oregon Health & Science Institute (OHSU), Portland
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT01042379CtDNA Based MRD Testing for NAC Monitoring in TNBC
- Oregon Oncology Specialists, Salem
RecruitingObservational study
Ages 18 and older · Women · Updated Jan 7, 2025 · NCT06230185From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.